Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial

Richard S. Finkel, Erika Finanger, Krista Vandenborne, H. Lee Sweeney, Gihan Tennekoon, Perry B. Shieh, Rebecca Willcocks, Glenn Walter, William D. Rooney, Sean C. Forbes, William T. Triplett, Sabrina W. Yum, Maria Mancini, James MacDougall, Angelika Fretzen, Pradeep Bista, Andrew Nichols, Joanne M. Donovan

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Fingerprint

Dive into the research topics of 'Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial'. Together they form a unique fingerprint.

Medicine & Life Sciences